Straits Times Index
3,348.87 +12.28 (+0.37%) S&P 500
5,286.22 +8.71 (+0.17%) Dow
38,595.42 -90.90 (-0.23%) Nasdaq
16,840.17 +105.16 (+0.63%) Bitcoin USD
69,809.41 +1,698.02 (+2.49%) CMC Crypto 200
1,505.70 +37.77 (+2.57%)
IQV Aug 2024 165.000 put
| Previous close | 2.9000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 165.00 |
| Expiry date | 2024-08-16 |
| Day's range | 2.9000 - 2.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 3 |
Simply Wall St.Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 33%?
Key Insights IQVIA Holdings' estimated fair value is US$325 based on 2 Stage Free Cash Flow to Equity IQVIA Holdings is...
- Simply Wall St.
Those who invested in IQVIA Holdings (NYSE:IQV) five years ago are up 67%
The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...
ReutersAnalysis-Weight-loss drug forecasts jump to $150 billion as supply grows
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.
